Dallas, Texas 11/26/2013 (Financialstrend) – Pfizer Inc. (NYSE:PFE), the pharmaceutical major has commenced its holiday season, by launching its drug for cough and chest congestion Robitussin – in a new variation: capsules filled with the drug in the liquid form.
With the commencement of the holiday season, out-bound Americans increase their chances of flu, cough especially during the travelling processes. Pfizer, in an attempt to provide complete flu-cold-chest congestion alleviating drug has announced ‘’Robitussin® Maximum Strength Cough + Chest Congestion DM.’’
Also popular as the drug to prevent the ‘COUGHequences’ of holiday season afflictions, Robitussin in the liquid form is expected to deliver quicker and more immediate relief when on travel.
This drug is available in a variety of product forms created to treat different symptoms for different age groups, including a product for treating cough during night-cycles called the ‘‘Maximum Strength Nighttime Cough DM.’’
Grows to 9th major pharma company in India
In other news for the research-based pharma manufacturer, two arms of its India operations have merged to form the 9th largest pharma company in India.
The announcement made on Nov 24, involves the official merger of two of its affiliates in India – Pfizer Ltd and Wyeth Ltd- and will be listed henceforward as Pfizer Ltd.
Pfizer Inc, based in the US, after acquiring rival Wyeth in 2009, continued operating Pfizer-owned Indian facilities and Wyeth-owned units as separate entities.
Pfizer, it appears has now thought it to be perfect timing to consolidate operations under single brand Pfizer. This will now give the company increased market share of 2.9% as against individual share of 1.9% held by Pfizer Ltd before the merger.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: